Merck’s (MRK) latest quarterly results saw EPS turn negative due to a massive charge from business development (BD) activities. However, beneath the surface, core product performance and future growth strategies remain more robust than ever, defying initial market concerns.
Earnings Summary (Actual vs. Expected)
| Metric | Actual (Current) | QoQ Change | Vs. Consensus |
|---|---|---|---|
| Revenue | $ 16.29B | -0.7% | +2.9% |
| Net Income | $ -3.16B | -160.5% | +15.5% |
| EPS | $ -1.28 | -161.2% | +15.2% |
While EPS fell to -$1.28 from $2.22 a year ago, it still beat the market consensus of -$1.47. Revenue grew 5.1% year-over-year, demonstrating solid top-line momentum despite the headline loss.
Key Earnings Highlights
- Core Product Strength: The flagship oncology drug Keytruda grew by 8%, while new launches like Winrevair ($525M) and Capvaxive ($142M) successfully gained traction, driving overall growth.
- One-time Cost Impact: The net loss was primarily driven by a $9 billion one-time charge related to Sedera. This is a strategic investment to secure future pipelines rather than a fundamental business failure.
- Mixed Segment Performance: Animal Health contributed to growth, while Gardasil sales declined by 22%, partially offsetting gains in other areas.
Future Strategy: Roadmap to $70B by 2030s
- Accelerating Launches: Merck plans to accelerate over 20 new launches, nearly all with blockbuster potential, aiming for over $70 billion in revenue by the mid-2030s.
- Strategic M&A: The company continues to target deals ranging from $1B to $15B, focusing on differentiated science in oncology, immunology, and cardiovascular-metabolic fields.
- AI-Driven R&D Innovation: Through a multi-year partnership with Google Cloud and collaborations with Tempus and Mayo Clinic, Merck is scaling advanced AI to boost R&D productivity and accelerate precision oncology.
The transition to a negative EPS this quarter is not a sign of fundamental weakness, but rather ‘strategic debt’ taken on to fuel future growth. The $9B charge may weigh down the balance sheet temporarily, but the underlying performance beat consensus, proving the company’s resilience.
Merck’s consistent dividend policy remains a key pillar of support for its stock price. Any volatility caused by these one-time costs should be viewed as a strategic entry point, offering a chance to acquire a high-quality pipeline and reliable dividend yield at a discount.
Read Together
Stock Analysis
[Analysis] Merck (MRK): Keytruda’s Cash Flow Powers 21 Years of Dividend Growth